Shoulo thrombolytic therapy be administered in the mobile intensive care unit in patients with evolving myocardial infarction? A pilot study
Arie Roth(Tel Aviv University), Shlomo Laniado, Hanoch Hod(University of Nottingham), Gabriel I. Barbash(Tel Aviv University), Hylton I. Miller(Tel Aviv University), Gad Keren(Assuta Medical Center), Yedael Har‐Zahav(Sheba Medical Center), Elieser Kaplinsky(Tel Aviv University), Michaela Modan(Tel Aviv University), S Rath(Tel Aviv University), Samuel Bassan
Cited by 98
Related Papers
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations
|Journal of the American College of Cardiology|2000|731
The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study
|Journal of the American College of Cardiology|2001|646
Neutrophil/lymphocyte ratio is related to the severity of coronary artery disease and clinical outcome in patients undergoing angiography
|Atherosclerosis|2012|390
Role of Naturally Occurring CD4 <sup>+</sup> CD25 <sup>+</sup> Regulatory T Cells in Experimental Atherosclerosis
|Arteriosclerosis Thrombosis and Vascular Biology|2007|347